Biomedical Engineering Reference
In-Depth Information
TOP INSTITUTE PHARMA CONSORTIUM: WWW.TIPHARMA.COM
Members
Agendia, Nycomed, Astra Zeneca, Bio Detection Systems,
Centocor/Johnson & Johnson, DNAge, Eli Lilly, GSK,
Hal Allergy, IQCorporation ISA, Lundbeck, Merck,
Netherlands Vaccine Institute, Nobilon, NOTOX,
Novartis, Numico, Octoplus, Organon, Pamgene,
Pepscan systems, Pfi zer, PRA International, Prosensa,
PROXY laboratories, Pyxis Discovery, Solvay
Pharmaceuticals, Winap, Xendo; plus 25 universities and
medical centres in Holland
Objectives
and
deliverables
TI Pharma is focused on the development of
tools required to shorten drug development
timelines and a reduction of the major risks of
clinical failure of potential new medicines. TI
Pharma aims to attain a position as a leading
pharmaceutical research and training institute in
Europe and hence a coordinating partner in
European research networks.
Description of
consortium
TI Pharma is a collaborative research structure
consisting of pharma and academic groups.
Individual projects are managed centrally
from a funding perspective; partners also contribute
in kind (with data and time). Ph.D. students and
postdoctoral fellows are responsible for the daily
research activities. Research is conducted at the
institutes brought together by TI Pharma, focused on six
main themes: autoimmune diseases, cardiovascular
diseases, cancer, infections/vaccines, brain diseases,
effi ciency analysis of the process of drug discovery and
development. There also seven technological disciplines:
therapeutic target fi nding; validation and animal
Models; lead selection and in silico and PK/PD
modeling; predictive drug disposition and toxicology;
biomarkers and biosensors; drug formulation, delivery,
and targeting; pharmaceutical production technologies;
molecular informatics.
Time frame
TI Pharma started mid - 2006
Current status
Forthy - eight research projects have been initiated
by end 2009 with 340 postdoctoral researchers
and students. One hundred twenty-six papers were
accepted for publication in 2009 and fi ve patents
fi led with seven pending. In 2009 the consortium
underwent a scientifi c review that recommended
continuation.
Search WWH ::
Custom Search